Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Guardant Health, Inc. - Common Stock (NQ: GH )

43.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Buys $10.5M In Google, Loads Up Another $31.6M In Zoom
Cathie Wood-led Ark Investment Management on Thursday bought 4,496 shares, estimated to be worth about $10.55 million, in Google parent Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG... 
Via Benzinga
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer
The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras... 
Via Benzinga
Exposures Product Safety
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had... 
Via Benzinga
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Loads Up Another $292K In SpaceX Partner Velo3D's SPAC
Cathie Wood-led Ark Investment Management on Wednesday bought 29,301 shares, estimated to be worth about $292,131, in the SPAC Jaws Spitfire Acquisition Corp (NYSE: SPFR)... 
Via Benzinga
Where Guardant Health Stands With Analysts
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 0 1... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
Cathie Wood Buys Another $42M In Twitter Stock, Also Adds DraftKings, Netflix
Cathie Wood-led Ark Investment Management on Monday bought 731,775 shares, estimated to be worth about $41.76 million, in Twitter Inc (NYSE: TWTR) — a day after The Bill and... 
Via Benzinga
Cathie Wood Loads Up Yet Another $51M In Coinbase As Shares Slump Amid Bitcoin-Led Crypto Carnage
Cathie Wood-led Ark Investment Management on Friday snapped up another 223,181 shares, worth about $50.7 million, in Coinbase Global Inc 
Via Benzinga
With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble?
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses. 
Via The Motley Fool
Exposures COVID-19
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
From Guardant Health, Inc.
Via Business Wire
Why Exact Sciences Stock Soared Today
The company's Cologuard DNA test appears to be in good shape to maintain its market leadership. 
Via The Motley Fool
Guardant Had Colon Cancer Data, But Rival Exact Popped — Here's Why
Guardant and Exact are in a "win-win situation," an analyst said Thursday as EXAS stock surged on a comparison to Guardant in colon cancer detection. 
Via Investor's Business Daily
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Exact Sciences' First-Quarter Results Show Its Strength Under Pressure
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate? 
Via The Motley Fool
3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming
Falling costs are ushering in a new era of screening for a dreaded disease. 
Via The Motley Fool
What 7 Analyst Ratings Have To Say About Guardant Health
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1... 
Via Benzinga
Guardant Health Inc (GH) Q1 2021 Earnings Call Transcript
GH earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers T2 Biosystems (NASDAQ:TTOO) share... 
Via Benzinga
Guardant Health Reports First Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
From Guardant Health, Inc.
Via Business Wire
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
From Guardant Health
Via Business Wire
Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Disruptor Alert: These 2 Companies Are Changing Cancer Care
Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.